Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver Range Resources: A hidden gem in the mining industry (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Insmed Inc INSM

Healthcare Biotechnology
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs... see more

Recent & Breaking News (NDAQ:INSM)

Insmed to Present at Two November Conferences

PR Newswire November 5, 2019

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire November 4, 2019

Insmed Reports Third Quarter 2019 Financial Results and Provides Business Update

PR Newswire October 30, 2019

Insmed to Host Third Quarter 2019 Financial Results Conference Call on Wednesday, October 30, 2019

PR Newswire October 23, 2019

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire October 7, 2019

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire September 5, 2019

Insmed to Present at Two September Conferences

PR Newswire September 3, 2019

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire August 2, 2019

Insmed Reports Second Quarter 2019 Financial Results and Provides Business Update

PR Newswire August 1, 2019

Insmed to Host Second Quarter 2019 Financial Results Conference Call on Thursday, August 1, 2019

PR Newswire July 25, 2019

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire July 2, 2019

Insmed Announces Closing of Public Offering of Common Stock

PR Newswire June 26, 2019

Insmed to Present at the Goldman Sachs 40th Annual Global Healthcare Conference

PR Newswire June 6, 2019

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire June 4, 2019

Insmed Announces Closing of Public Offering of Common Stock

PR Newswire May 24, 2019

Insmed Announces Pricing of Public Offering of Common Stock

PR Newswire May 21, 2019

Insmed Reports First Quarter 2019 Financial Results and Provides Business Update

PR Newswire May 7, 2019

Insmed to Host First Quarter 2019 Financial Results Conference Call on Tuesday, May 7, 2019

PR Newswire April 30, 2019

Insmed Granted Additional U.S. Patent For ARIKAYCE® (amikacin liposome inhalation suspension), Strengthening Brand's Global Patent Portfolio

PR Newswire April 9, 2019

Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch

PR Newswire April 8, 2019